290 related articles for article (PubMed ID: 33969073)
1. Detection of
Kim B; Kim Y; Park I; Cho JY; Lee KA
World J Clin Cases; 2021 Apr; 9(12):2884-2889. PubMed ID: 33969073
[TBL] [Abstract][Full Text] [Related]
2. Characteristics of Genomic Alterations in Pericardial Effusion of Advanced Non-small Cell Lung Cancer.
He J; Hu X; Chen L; Liu Q; Jiang Y
Front Genet; 2022; 13():850290. PubMed ID: 35646096
[No Abstract] [Full Text] [Related]
3. Monitoring of somatic mutations in circulating cell-free DNA by digital PCR and next-generation sequencing during afatinib treatment in patients with lung adenocarcinoma positive for EGFR activating mutations.
Iwama E; Sakai K; Azuma K; Harada T; Harada D; Nosaki K; Hotta K; Ohyanagi F; Kurata T; Fukuhara T; Akamatsu H; Goto K; Shimose T; Kishimoto J; Nakanishi Y; Nishio K; Okamoto I
Ann Oncol; 2017 Jan; 28(1):136-141. PubMed ID: 28177428
[TBL] [Abstract][Full Text] [Related]
4. Picoliter-Droplet Digital Polymerase Chain Reaction-Based Analysis of Cell-Free Plasma DNA to Assess EGFR Mutations in Lung Adenocarcinoma That Confer Resistance to Tyrosine-Kinase Inhibitors.
Seki Y; Fujiwara Y; Kohno T; Takai E; Sunami K; Goto Y; Horinouchi H; Kanda S; Nokihara H; Watanabe S; Ichikawa H; Yamamoto N; Kuwano K; Ohe Y
Oncologist; 2016 Feb; 21(2):156-64. PubMed ID: 26768482
[TBL] [Abstract][Full Text] [Related]
5. Clinical Utility of Cell-Free DNA for the Detection of
McCoach CE; Blakely CM; Banks KC; Levy B; Chue BM; Raymond VM; Le AT; Lee CE; Diaz J; Waqar SN; Purcell WT; Aisner DL; Davies KD; Lanman RB; Shaw AT; Doebele RC
Clin Cancer Res; 2018 Jun; 24(12):2758-2770. PubMed ID: 29599410
[No Abstract] [Full Text] [Related]
6. Variants with a low allele frequency detected in genomic DNA affect the accuracy of mutation detection in cell-free DNA by next-generation sequencing.
Wang JF; Pu X; Zhang X; Chen K; Xi Y; Wang J; Mao X; Zhang J; Heymach JV; Antonoff MB; Hofstetter WL; Mehran RJ; Rice DC; Roth JA; Sepesi B; Swisher SG; Vaporciyan AA; Walsh GL; Meng QH; Shaw KR; Eterovic AK; Fang B
Cancer; 2018 Mar; 124(5):1061-1069. PubMed ID: 29178133
[TBL] [Abstract][Full Text] [Related]
7. Use of Low-Frequency Driver Mutations Detected by Cell-Free Circulating Tumor DNA to Guide Targeted Therapy in Non-Small-Cell Lung Cancer: A Multicenter Case Series.
Jacobs MT; Mohindra NA; Shantzer L; Chen IL; Phull H; Mitchell W; Raymond VM; Banks KC; Nagy RJ; Lanman RB; Christensen J; Patel JD; Clarke J; Patel SP
JCO Precis Oncol; 2018 Nov; 2():1-10. PubMed ID: 35135131
[TBL] [Abstract][Full Text] [Related]
8. Concordance between genomic alterations assessed by next-generation sequencing in tumor tissue or circulating cell-free DNA.
Chae YK; Davis AA; Carneiro BA; Chandra S; Mohindra N; Kalyan A; Kaplan J; Matsangou M; Pai S; Costa R; Jovanovic B; Cristofanilli M; Platanias LC; Giles FJ
Oncotarget; 2016 Oct; 7(40):65364-65373. PubMed ID: 27588476
[TBL] [Abstract][Full Text] [Related]
9. Mechanisms of primary resistance to EGFR targeted therapy in advanced lung adenocarcinomas.
Jin Y; Shi X; Zhao J; He Q; Chen M; Yan J; Ou Q; Wu X; Shao YW; Yu X
Lung Cancer; 2018 Oct; 124():110-116. PubMed ID: 30268447
[TBL] [Abstract][Full Text] [Related]
10. Detection of Loss of Heterozygosity in cfDNA of Advanced
Boldrin E; Nardo G; Zulato E; Bonanno L; Polo V; Frega S; Pavan A; Indraccolo S; Saggioro D
Int J Mol Sci; 2019 Dec; 21(1):. PubMed ID: 31861832
[TBL] [Abstract][Full Text] [Related]
11. Association of EGFR L858R Mutation in Circulating Free DNA With Survival in the EURTAC Trial.
Karachaliou N; Mayo-de las Casas C; Queralt C; de Aguirre I; Melloni B; Cardenal F; Garcia-Gomez R; Massuti B; Sánchez JM; Porta R; Ponce-Aix S; Moran T; Carcereny E; Felip E; Bover I; Insa A; Reguart N; Isla D; Vergnenegre A; de Marinis F; Gervais R; Corre R; Paz-Ares L; Morales-Espinosa D; Viteri S; Drozdowskyj A; Jordana-Ariza N; Ramirez-Serrano JL; Molina-Vila MA; Rosell R;
JAMA Oncol; 2015 May; 1(2):149-57. PubMed ID: 26181014
[TBL] [Abstract][Full Text] [Related]
12. Detection of EGFR Mutations in cfDNA and CTCs, and Comparison to Tumor Tissue in Non-Small-Cell-Lung-Cancer (NSCLC) Patients.
Liu HE; Vuppalapaty M; Wilkerson C; Renier C; Chiu M; Lemaire C; Che J; Matsumoto M; Carroll J; Crouse S; Hanft VR; Jeffrey SS; Di Carlo D; Garon EB; Goldman J; Sollier E
Front Oncol; 2020; 10():572895. PubMed ID: 33117705
[TBL] [Abstract][Full Text] [Related]
13. Next-generation sequencing reveals mutational accordance between cell-free DNA from plasma, malignant pleural effusion and ascites and directs targeted therapy in a gastric cancer patient.
Zhou S; Xu B; Qi L; Zhu D; Liu B; Wei J
Cancer Biol Ther; 2019; 20(1):15-20. PubMed ID: 30118648
[TBL] [Abstract][Full Text] [Related]
14. Profiling of circulating tumor DNA in plasma of non-small cell lung cancer patients, monitoring of epidermal growth factor receptor p.T790M mutated allelic fraction using beads, emulsion, amplification, and magnetics companion assay and evaluation in future application in mimicking circulating tumor cells.
Garcia J; Wozny AS; Geiguer F; Delherme A; Barthelemy D; Merle P; Tissot C; Jones FS; Johnson C; Xing X; Xu Z; Edelstein DL; Brevet M; Souquet PJ; Rodriguez-Lafrasse C; Payen L; Couraud S
Cancer Med; 2019 Jul; 8(8):3685-3697. PubMed ID: 31112372
[TBL] [Abstract][Full Text] [Related]
15. A nanowire-based liquid biopsy method using cerebrospinal fluid cell-free DNA for targeted management of leptomeningeal carcinomatosis.
Choi W; Cho Y; Park SY; Hwang KH; Han JY; Lee Y
J Cancer Res Clin Oncol; 2021 Jan; 147(1):213-222. PubMed ID: 32705364
[TBL] [Abstract][Full Text] [Related]
16. Prospective blinded study of somatic mutation detection in cell-free DNA utilizing a targeted 54-gene next generation sequencing panel in metastatic solid tumor patients.
Kim ST; Lee WS; Lanman RB; Mortimer S; Zill OA; Kim KM; Jang KT; Kim SH; Park SH; Park JO; Park YS; Lim HY; Eltoukhy H; Kang WK; Lee WY; Kim HC; Park K; Lee J; Talasaz A
Oncotarget; 2015 Nov; 6(37):40360-9. PubMed ID: 26452027
[TBL] [Abstract][Full Text] [Related]
17. Unique genetic profiles from cerebrospinal fluid cell-free DNA in leptomeningeal metastases of EGFR-mutant non-small-cell lung cancer: a new medium of liquid biopsy.
Li YS; Jiang BY; Yang JJ; Zhang XC; Zhang Z; Ye JY; Zhong WZ; Tu HY; Chen HJ; Wang Z; Xu CR; Wang BC; Du HJ; Chuai S; Han-Zhang H; Su J; Zhou Q; Yang XN; Guo WB; Yan HH; Liu YH; Yan LX; Huang B; Zheng MM; Wu YL
Ann Oncol; 2018 Apr; 29(4):945-952. PubMed ID: 29346604
[TBL] [Abstract][Full Text] [Related]
18. [Influence of Different Therapies on EGFR Mutants by Circulating Cell-free DNA of Lung Adenocarcinoma and Prognosis].
Su F; Zheng K; Fu Y; Wu Q; Tang Y; Wang W; Jiang L
Zhongguo Fei Ai Za Zhi; 2018 May; 21(5):389-396. PubMed ID: 29764589
[TBL] [Abstract][Full Text] [Related]
19. Assessment of EGFR mutation status using cell-free DNA from bronchoalveolar lavage fluid.
Park S; Hur JY; Lee KY; Lee JC; Rho JK; Shin SH; Choi CM
Clin Chem Lab Med; 2017 Aug; 55(10):1489-1495. PubMed ID: 28195541
[TBL] [Abstract][Full Text] [Related]
20. Cell-free DNA as a molecular tool for monitoring disease progression and response to therapy in breast cancer patients.
Liang DH; Ensor JE; Liu ZB; Patel A; Patel TA; Chang JC; Rodriguez AA
Breast Cancer Res Treat; 2016 Jan; 155(1):139-49. PubMed ID: 26667234
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
